Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Turnstone Biologics Corp.
Headquarters: La Jolla, CA, United States of America
Website: http://www.turnstonebio.com
Year Founded: 2015
Status: Public
Industry Sector: HealthTechnology
CEO: Sammy J. Farah, PhD, MBA
Number Of Employees: 80
Enterprise Value: $-62,251,394
PE Ratio: -0.11
Exchange/Ticker 1: NASDAQ:TSBX
Exchange/Ticker 2: N/A
Latest Market Cap: $8,583,000
BioCentury | Mar 5, 2025
Management Tracks
CFO Anthony Doyle resigns at Biocryst
Plus: Greenside succeeds CEO Mark DePristo at Bighat, and updates from Be Biopharma, 3t and Imugene
BioCentury | Nov 1, 2024
Management Tracks
Amy Rick joins FDA’s newly formed Rare Disease Innovation Hub
Plus: Will Kane named CCO, Venkat Ramanan CFO of Anthos, and an update from Breath Diagnostics
BioCentury | Oct 11, 2024
Management Tracks
Lilly names Fuchs inaugural chief AI officer
Plus: Turnstone restructures and Glycomine appoints a new chairperson
BioCentury | Aug 1, 2024
Finance
Venture Report: venBio closes new $528M fifth fund
Plus: Airna, ReviR, LTZ and Synthetica draw Series A cash, while Outpace, Confo and Healx refill their coffers
BioCentury | Feb 21, 2024
Management Tracks
Papa succeeds Miller as Emergent’s CEO
Plus: Paratus names Heah as CEO and updates from Jazz, Arvinas, KaliVir, Celcuity, QuidelOrtho, Turnstone and PhRMA
BioCentury | Sep 15, 2023
Finance
Friday IPOs: Warm reception for RayzeBio as Neumora sags in first-day trading
As a pair of biotechs raise a combined $540M in NASDAQ offerings, how have other listings in the sector fared in the aftermarket this year?
BioCentury | Aug 4, 2023
Finance
Biotechs that could enter the IPO queue as crossovers await liquidity
Among dozens of companies that raised crossover cash before markets turned sour, some may soon have what it takes to go public
BioCentury | Jul 22, 2023
Deals
July 21 Quick Takes: Gilead drops CD47 lead indication due to futility
Plus: Turnstone shares sag after upsized IPO, Idorsia unveils cost-cutting plan, and updates from ADC, the FTC, TVM, Verrica and more
BioCentury | Jun 13, 2023
Finance
Turnstone to test public markets’ appetite for a biotech still waiting for clinical data
Now focused on TILs with data due in mid-2024, the company would be the fourth biotech to raise at least $20M in a NASDAQ listing this year
BioCentury | Jul 22, 2021
Deals
July 21 Quick Takes: Turnstone’s $80M round to advance oncolytic virus, TIL programs
Plus: Vedanta, bluebird, Cytokinetics and more
Items per page:
1 - 10 of 11